Introduction
============

Lung cancer is still a leading cause of death among malignant tumors with 5-year survival rates of less than 15% [@B1]. It classified as either non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) and NSCLC accounts for approximately 85% of incidents [@B2]. Numerous factors lead to the low survival rates in NSCLC patients, such as the poor early detection, tumor recurrence and distant metastasis. Recurrence and metastasis remain a great challenge for cure despite the excellent outcomes of NSCLC after standard treatments. Some parameters including tumor size, tumor location, differentiation grade and the TNM stages for predicting local recurrence, distant metastasis and overall survival in patients with NSCLC have been identified [@B3]-[@B5]. Although the stage determined according to the Union for International Cancer Control (UICC) and the International Association for the Study of Lung Cancer (IASLC) TNM classification is important and useful for predicting the clinical outcome and determining the appropriate treatment, the OS varies widely, even in patients with the same stage of NSCLC. Robust and reliable prognostic factors might be helpful to allow treatment options and follow-up schemes to be tailored to the individual risk situation. Thus, the identification of an efficient and reliable marker to obtain additional prognostic information is essential. Discovering low cost, highly effective and easily accessible biomarkers for assessment of lung cancer prognosis is necessary.

There has been shown that systemic inflammatory response reflect the promotion of angiogenesis, DNA damage and tumor invasion through up-regulation of cytokines [@B6]-[@B8]. Based on this, a number of inflammation-based prognostic markers have been identified, such as CRP and fibrinogen [@B9], [@B10]. In addition, there is increasing evidence that serum CRP and plasma fibrinogen could effectively predict clinical outcome in patients with NSCLC [@B11]-[@B14]. Our previous results also showed that CRP was potential marker for poor prognosis in lung cancer [@B15]. Moreover, compared with other numerous prognostic factors, CRP and fibrinogen-based prognostic scores are simple, inexpensive and widely available from preoperative evaluation of blood test.

Recently, a growing studies reported that nomogram combined with the biomarkers of systemic inflammation response could provide more accurate prediction than conventional staging systems in a variety of tumors [@B16]-[@B19]. Nomograms are a pictorial representation of a complex mathematical formula. It use important factors to graphically depict a statistical prognostic model that used to estimate prognosis in oncology for a given individual [@B20]. Nomograms have been accepted as reliable and pragmatic prediction tools to quantify individual risk by incorporating a variety of important factors for oncological prognoses [@B21], [@B22]. In lung cancer, nomograms have been proved to provide more precise prediction compared with traditional TNM classification [@B23], [@B24]. However, there are few studies on establishing a prognostic nomogram for NSCLC based on CRP and plasma fibrinogen.

Herein, we established a prognostic nomogram for resettable NSCLC based on the clinicopathological parameters and the CRP and fibrinogen-based prognostic scores, to determine whether this model provides more accurate prediction of patient survival compared with the 7^th^ edition of AJCC TNM classifications.

Methods
=======

Sample collection and laboratory analysis
-----------------------------------------

We consecutively collected 856 lung cancer patients (ages 25-89 years, median 61 years, 612 males and 244 females) who underwent lung resection at Sun Yat-Sen University Cancer Center from December 2007 to October 2012. Inclusion criteria were as follows: (1) patients confirmed as lung cancer by pathological, pathologic slides were reviewed by two independent observers to classify histologic subtypes. (2) patients who underwent radical resection and had not previously taken anti-inflammatory medicines or anticoagulant therapy were included. (3) The absence of second carcinomas was assessed by clinical history, computed tomography (CT), ultra-sonographic examination and routine laboratory tests. Subjects with the following conditions were not included in the study: history of inflammatory disease that may modify CRP and fibrinogen levels, clinical suspicion or laboratory signs of bacterial or viral infection, fever of unknown origin. We collected clinicopathologic parameters of each patient as follows: age, gender, smoking history, tumor size, differentiation, pathologic TNM stage. Clinical stage was assessed according to the seventh edition of the Lung Cancer Staging International Division, which was published by the Union for International Cancer Control (UICC) and the International Association for the Study of Lung Cancer (IASLC) in 2009. Overall survival of patients was recorded based on a follow-up clinic or a telephone call. The date from surgery to death or to January 2015 was considered as survival time.

All the samples were collected at the time of diagnosis before any treatment. The serum CRP levels were assayed by nephelometry on an Automatic Biochemical Alnalyzer (Hitachi 7600, Japan) and plasma level of fibrinogen was measured by using a Dade thrombin reagent (Dade Behring, Germany) on an Automated Blood Coagulation Analyzer (CS-5100 Sysmex, Japan) according to the manufacturer\'s instructions.

Risk Group Stratification Based on the Nomogram
-----------------------------------------------

C-index was commonly used to evaluate the discrimination ability of a nomogram. Beyond this, according to the total risk scores (from highest to lowest) in the cohort, the NSCLC patients were grouped into different risk groups within a certain category, Kaplan-Meier curves were used to illustrate the survival outcomes of the NSCLC patients.

Statistical Analysis
--------------------

All statistical analyses were performed using the SPSS 20.0 statistical package (SPSS Inc., Chicago, IL, USA). Nomograms for possible prognostic factors associated with overall survival (OS) were established by R software version 3.14.1 (<http://www.rproject.org/>), and the predictive performance of the model was evaluated by concordance index (C-index). Survival rates were analyzed using the Kaplan-Meier method and compared by the log-rank test. Univariate and multivariate survival analyses and Death hazard ratio were performed using the Cox proportional hazards regression with conditional backward stepwise to identify independent prognostic factors. Pearson\'s χ^2^ test and *t*-test was used to investigate the correlations between two categorical variables. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using univariate and multivariate Cox proportional hazards regression models to estimate the effects of prognostic variables\' OS. All statistical tests were two-tailed and we considered *P* value less than 0.05 as statistically significant.

Results
=======

Clinicopathologic Characteristics
---------------------------------

856 patients met all criteria were enrolled for our study. The clinical characteristics of patients were shown in Table [1](#T1){ref-type="table"}. The median age was 61(range from 25 to 89). There existed 612 male patients (71.5%) and 244 female patients (28.5%). Over half patients (507, 59.23%) had smoking history. The number of patients of I, II, III and IV stage were 284 (16.94%), 137 (16%), 290 (33.88%) and 145 (16.94%) respectively. Lymph node metastasis was confirmed pathologically in 467 (54.56%) patients. 712 (83.18%) patients have distant metastasis. 290 (33.88%) and 14 (1.64%) patients have chemotherapy and radiotherapy respectively. And it included 538 adenocarcinoma (ADC), 256 squamous cell carcinoma (SCC), 4 large cell carcinoma (LC) and 58 other carcinomas.

Association of preoperative serum CRP and plasma fibrinogen levels with clinical characteristics
------------------------------------------------------------------------------------------------

Median survival time in the present group of patients was 26 months (range 4-85 months), the death occurred in 618 (72.20%) of the 856 lung cancer patients. The 3-, 5-year survival rate were 38.32%, 15.78%, respectively. Patient characteristics and correlations between preoperative CRP, fibrinogen levels and clinicopathological parameters are shown in Table [2](#T2){ref-type="table"}. Male and ever smoking patients had higher preoperative CRP and fibrinogen levels (*P* \< 0.001). And CRP and fibrinogen levels were also associated with tumor status, lymph node metastasis, distant metastases and clinical stage (*P* \< 0.001). There was no correlation between fibrinogen, CRP and age, differentiation, chemotherapy, radiotherapy. Moreover, patients who experienced poor outcome had significantly higher preoperative CRP and fibrinogen levels compared to patients with better prognosis (*P* \< 0.001).

Association of preoperative CRP and fibrinogen with survival
------------------------------------------------------------

X-tile program was used to determine the optimal cut-off values for CRP, fibrinogen of OS, which were 3.7g/L and 8.6g/L, respectively (Figure [1](#F1){ref-type="fig"}). In NSCLC patients, the five-year OS rate was 15.78% (Figure [2](#F2){ref-type="fig"}A). Kaplan-Meier curves revealed that patients with higher level of pretreatment CRP and fibrinogen had a significantly shorter overall survival (Figure [2](#F2){ref-type="fig"}B, 2C, Table [3](#T3){ref-type="table"}, *P* \< 0.001). Combined CRP, fibrinogen expression and overall survival were also investigated. The patients were divided into three groups: both low, either high and both high. There was significant difference among three groups for overall survival (Figure [2](#F2){ref-type="fig"}D, Table [3](#T3){ref-type="table"}, *P* \< 0.001). The univariate analysis show that preoperative CRP and fibrinogen levels were found to be associated with OS, along with other variables, such as age, gender, smoking history, differentiation, tumor status, nodal status, clinical stage (Table [4](#T4){ref-type="table"}, all *P* \< 0.05). CRP and fibrinogen were identified as independent prognostic factor for OS using the Cox proportional hazard model (HR = 1.399, 95% CI: 1.122-1.744, *P* = 0.003; HR = 1.304, 95% CI: 1.040-1.636, *P* = 0.022, respectively). Moreover, multivariate analysis by Cox regression showed that tumor status (HR = 1.281, *P* = 0.009), nodal status (HR = 1.721, *P* \< 0.001), distant metastases (HR = 1.495, P \< 0.001), clinical stage (HR = 2.009, *P* \< 0.001) were as identified independent prognostic factors of overall survival for NSCLC patients.

The nomogram for the prediction of OS
-------------------------------------

To predict OS, two nomograms were established by multivariate Cox regression model according to all significantly independent factors for OS. A nomogram containing CRP, fibrinogen and TNM characteristics was developed based on the results of multivariate logistic regression analysis (Figure [3](#F3){ref-type="fig"}A), this nomogram achieved a C-index of 0.720 (95% CI: 0.671-0.769) for OS prediction. The calibration curves for the probalility of survival at 5 years after surgery showed optimal agreement between the prediction established in the nomogram and the actual observation (Figure [3](#F3){ref-type="fig"}B). And the optimal cut-off value for fibrinogen and CRP of OS were 3.7g/L and 8.6mg/L, respectively. Another nomogram containing the TNM staging system achieved a C-index of 0.689 (95% CI: 0.668-0.709) (Figure [3](#F3){ref-type="fig"}C), the calibration curves for the probalility of survival at 5 years after surgery were also fitted well (Figure [3](#F3){ref-type="fig"}D). Compared with the TNM staging system, the C-index of the CRP and fibrinogen nomogram was significantly higher than the C-index of the seventh TNM classification (P \< 0.05). The results suggested that the nomogram based on CRP and fibrinogen is better than the AJCC TNM classifications in prognostic prediction. In addition, we have compared the predictive value of the nomogram with other currently available models [@B25]-[@B27] (Table [S1](#SM1){ref-type="supplementary-material"} a,b,c).

Performance of the nomogram in stratifying risk of patients
-----------------------------------------------------------

Based on the linear predictor of nomogram, four subgroups were divided in NSCLC patients after sorting by total score (score: 0-158, 158-258, 258-352, ≥352) (Table [5](#T5){ref-type="table"}, Table [S2](#SM1){ref-type="supplementary-material"}) and Kaplan-Meier curves were plotted, each of which represented a distinct prognosis. The NSCLC patients were stratified into different risk subgroups after applying the cutoff values. Moreover, there was significant distinction between Kaplan-Meier curves for survival outcomes within each TNM category (*P* = 0.0011, *P* = 0.0421, *P* = 0.0041, *P* = 0.0081) (Figure [4](#F4){ref-type="fig"}). In all, this stratification could effectively discriminate the survival outcomes for the four proposed risk groups.

Discussion
==========

NSCLC is an aggressive cancer with high incidence and death rate in worldwide [@B28]. The survival of individual patients are remarkably heterogeneous in NSCLC, even within the same stage [@B29]. The TNM staging system of NSCLC is commonly used for predicting cancer survival [@B30]. Nomogram is a simple graphical representation of a statistical prediction model that generates a numerical probability of a clinical event, such as death and cancer recurrence [@B20], [@B31]. In recent years, nomograms have been constructed in a variety of cancers, and some of them have been found to be more reliable prediction than the traditional staging system [@B23], [@B32]-[@B34]. Moreover it has been validated to compare favorably to the traditional TNM staging systems in many cancers, and thus have been identified as an alternative or even a new standard [@B22], [@B35], [@B36]. A number of studies also found that in patients with NSCLC, nomograms were accurate to predict the risk of a node\'s involvement [@B37], [@B38], the individual risk of developing metastasis to the brain and had strong performance in individualize patient decision making [@B39].

Numbers of studies suggested that serum CRP and plasma fibrinogen could be used as an independent prognostic factor for lung cancer [@B40]-[@B42]. However, studies combining the two-significant prognostic factor, serum CRP and plasma fibrinogen are rare. Could the combination achieve more efficient prognostic performance? Considering the advantage of clinical nomogram, we attempted to establish a predictive nomogram to predict the survival outcomes of resected NSCLC patients based on serum CRP, plasma fibrinogen and other prognostic factors. In this study, using univariable analysis and subsequent multivariable analysis, we identified tumor size, nodal status, distant metastases, clinical stage, fibrinogen and CRP as independent prognostic factors for surgically treated NSCLC patients. In line with the previous studies, the levels of CRP and fibrinogen were significant prognostic markers for resected NSCLC patients [@B11]-[@B14]. A nomogram for predicting survival was developed and these six variables were incorporated into the nomogram. The C-index of the nomogram based on CRP and fibrinogen predicted OS with an accuracy of 0.72, which showed significantly better prediction of OS than the 7^th^ TNM staging system. The calibration plots revealed good correlation between the predicted survival probability and the actual survival rate. The decision curve analysis showed more potential of clinical application of the prediction models compared with TNM staging system. According to X-tile program, the cut-off value of CRP and fibrinogen were 8.6 mg/L, 3.7 g/L respectively. The clinical characteristics of gender, smoking history, differentiation, tumor status, lymph node metastasis, distant metastases, clinical stage and overall survival were all associated with serum CRP and plasma fibrinogen levels. Even patients with the disease in same TNM category were divided into four risk groups, and each group had distinct survival outcomes in which patients in high-risk subgroup had shorter OS. Moreover, the measurement of serum CRP and plasma fibrinogen is relatively inexpensive and routinely conducted during preoperative examinations. Therefore our nomogram is a reliable tool to predict survival in resectable NSCLC and is helpful to make individualized treatment decision.

Several potential mechanisms can probably be used to explain the prognostic values of the inflammatory biomarker CRP and fibrinogen for NSCLC. Firstly, cancer cells interact directly and indirectly with host inflammatory cells. This tumor-associated inflammatory response may lead to an alteration in cancer cell biology and activation of stromal cells in the tumor microenvironment by up-regulation of cytokines and inflammatory mediators, such as interleukin-6 (IL-6), interleukin-1, interleukin-2, tumor necrosis factor (TNF), and these cytokines are all known to trigger the production of CRP and fibrinogen production [@B43], [@B44]. CRP is an acute-phase protein of inflammatory response, which is produced in the liver. It is very likely that the response to systemic inflammation makes CRP as important mediators linking inflammation and cancer [@B45], [@B46]. Fibrinogen is primarily produced in the liver and is converted by the proteolytic action of thrombin. The elevated plasma fibrinogen levels reflect the status of tumor cell-host interactions, and the cellular interactions may be serving as an important contributing factor in cancer development including cell migration, promotion, and inflammatory mediators [@B47], [@B48]. Secondly, Evaluated CRP and fibrinogen are indicators of tumor-associated inflammatory response, which is companied by up-regulation of cytokines and inflammatory mediators, inhibition of apoptosis, induction of angiogenesis, stimulation of DNA damage and immunosuppression and remodelling of the extracellular matrix, hence promoting tumor growth and metastasis [@B6], [@B7]. Thirdly, some growth factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF-2), binds to fibrinogen and contact with tumor cells, thus promotes tumor proliferation and stimulates angiogenesis [@B49], [@B50].

Although the nomogram in our study could predict survival more precise for patients with resected NSCLC, there are still several limitations in this study. First, this is a single-center study. Second, our study was a retrospective study, and there may exist selection bias during retrospective data collection. Third, it lacks validation cohort, which could further prove its robustness beyond current data. Therefore, our results need to be further verified in a prospective, large-scale collaborative study. Moreover, the detail mechanisms for better predictive value of CRP and fibrinogen were unknown, exploring the mechanisms of CRP and fibrinogen as independent prognostic factors for surgically treated NSCLC patients is our following aim.

In conclusion, we established a nomogram containing CRP and fibrinogen for predicting survival of patients with resected NSCLC, and it shows superior discrimination ability compared with traditional TNM staging. This model is a simple and easy-to-use scoring system for clinicians and patients to more precisely estimate the survival of individual patients after surgery and identify subgroups of patients who are in need of a specific treatment strategy.
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![X-title analyses of 5-year OS was performed using patients\' data to determine the optimal cut-off value for CRP (A, B, C) and fibrinogen (D, E, F).](jcav08p0744g001){#F1}

![The 5-year OS rate was 15.78% of 856 NSCLC patients(A); Survival curves for overall survival (OS) according to CRP (B), fibrinogen (C), and their combined (D) expression status.](jcav08p0744g002){#F2}

![Nomogram convey the results of prognostic models using CRP, fibrinogen and TNM characteristics predict OS (A). Calibration curve for predicting 5-year OS rate in the nomogram (B), the C-index for OS were 0.720. Nomogram convey the results of prognostic models using TNM system staging (C). Calibration curve for predicting 5-year OS rate in the nomogram (D), the C-index for OS were 0.689. The x-axis is nomogram-predicted probility of survival and y-axis is actual survival. The reference line is 45 degree and indicates perfect calibration.](jcav08p0744g003){#F3}

![Risk group stratification within each TNM stage in the NSCLC patients. Kaplan-Meier curves of OS according to the score predicted OS shown in the nomograms.](jcav08p0744g004){#F4}

###### 

Clinicopathological characteristics of NSCLC patients.

  Demographic or characteristic   Number                         Percent(%)   
  ------------------------------- ------------------------------ ------------ -------
  Gender                          male                           612          71.5
                                  famale                         244          28.5
  Age                             median                         61           \-
                                  range                          25-89        \-
  Smoking history                 Yes                            507          59.23
                                  No                             349          40.77
  Clinical stage                  I                              284          33.18
                                  II                             137          16
                                  III                            290          33.88
                                  IV                             145          16.94
  T status                        T1                             145          16.94
                                  T2                             488          57.01
                                  T3                             111          13.97
                                  T4                             112          13.08
  N status                        N0                             389          45.44
                                  N1                             140          16.36
                                  N2                             278          32.48
                                  N3                             49           5.72
  M status                        M0                             712          83.18
                                  M1                             144          16.82
  Chemotherapy                    Yes                            290          33.88
                                  No                             566          66.12
  Radiotherapy                    Yes                            14           1.64
                                  No                             842          98.36
  Category                        adenocarcinoma(ADC)            538          62.85
                                  squamous cell carcinoma(SCC)   256          29.90
                                  large cell carcinoma(LC)       4            0.47
                                  other                          58           6.78

###### 

Correlation between Fibrinogen, CRP and clinicopathological variables of NSCLC patients.

  Variables               Cases (n=856)   Fibrinogen (3.7g/L)   Patients, n (%)   CRP (8.6g/L)   Patients, n (%)                                                                     
  ----------------------- --------------- --------------------- ----------------- -------------- ----------------- ----------- ------------- ----------- ------------- ------------- -----------
  Age (years)                                                   0.155                                              0.243                     0.968                                   0.926
  \<=61                   119             3.61±1.38                               73 (61.3%)     46 (38.7%)                    14.47±28.35               64 (53.8%)    55 (46.2%)    
  \>61                    737             3.80±1.34                               410 (55.6%)    327 (44.4%)                   14.37±24.41               393 (53.3%)   344 (46.7%)   
  Gender                                                                                                                                                                             
  male                    612             3.91±1.41             \<0.001\*         314 (51.3%)    298 (48.7%)       \<0.001\*   16.97±26.85   \<0.001\*   280 (45.8%)   332 (54.2%)   \<0.001\*
  Famale                  244             3.41±1.08                               169 (69.3%)    75 (30.7%)                    7.90±17.96                177 (72.5%)   67 (27.5%)    
  Smoking history                                                                                                                                                                    
  no                      349             3.46±1.15             \<0.001\*         228 (65.3%)    121 (34.7%)       \<0.001\*   9.06±18.81    \<0.001\*   235 (67.3%)   114 (32.7%)   \<0.001\*
  yes                     507             3.98±1.42                               255 (50.3%)    252 (49.7%)                   18.05±27.88               222 (43.8%)   285 (56.2%)   
  Differentiation                                                                                                                                                                    
  G1                      41              3.59±1.39             0.388             25 (61.0%)     16 (39.0%)        0.547       13.77±26.87   0.872       25 (61.0%)    16 (39.0%)    0.318
  G2/G3                   815             3.78±1.34                               458 (56.2%)    357 (43.6%)                   14.41±24.89               432 (53.0%)   383 (47.0%)   
  Tumor status (T)                                                                                                                                                                   
  T1/T2                   633             3.57±1.24             \<0.001\*         402 (63.5%)    231 (36.5%)       \<0.001\*   10.35±19.96   \<0.001\*   389 (61.5%)   244 (38.5%)   \<0.001\*
  T3/T4                   223             4.33±1.46                               81 (36.3%)     142 (63.7%)                   25.83±33.00               68 (30.5%)    155 (69.5%)   
  Lymph node metastasis                                                                                                                                                              
  No                      389             3.62±1.32             0.003\*           241 (62.0%)    148 (38.0%)       0.003\*     11.10±20.82   \<0.001\*   238 (61.2%)   151 (38.8%)   \<0.001\*
  Yes                     467             3.89±1.36                               242 (51.8%)    225 (48.2%)                   17.11±27.70               219 (46.9%)   248 (53.1%)   
  Distant metastases                                                                                                                                                                 
  M0                      712             3.71±1.33             0.005\*           418 (58.7%)    294 (41.3%)       0.003\*     13.73±24.99   0.091       392 (55.1%)   320 (44.9%)   0.03\*
  M1                      144             4.06±1.40                               65 (45.1%)     79 (54.9%)                    17.59±24.72               65 (45.1%)    79 (54.9%)    
  Clinical stage                                                                                                                                                                     
  I/II                    421             3.55±1.30             \<0.001\*         278(66.0%)     143(34.0%)        \<0.001\*   11.14±22.04   \<0.001\*   264(62.7%)    157(37.3%)    \<0.001\*
  III/IV                  435             3.98±1.35                               205(47.1%)     230(52.9%)                    17.52±27.17               193(44.4%)    242(55.6%)    
  Chemotherapy                                                                                                                                                                       
  No                      566             3.72±1.34             0.141             326(57.6%)     240(42.4%)        0.334       13.61±24.41   0.207       306(54.1%)    260(45.9%)    0.580
  Yes                     290             3.86±1.36                               157(54.1%)     133(45.9%)                    15.89±26.01               151(52.1%)    139(47.9%)    
  Radiotherapy                                                                                                                                                                       
  No                      842             3.78±1.35             0.059             473(56.2%)     369(43.8%)        0.290       14.46±25.13   0.466       451(53.6%)    391(46.4%)    0.426
  Yes                     14              3.09±0.97                               10(71.4%)      4(28.6%)                      9.55±12.07                6(42.9%)      8(57.1%)      
  Overall survial                                                                                                                                                                    
  Alive                   238             3.37±1.24             \<0.001\*         177(74.4%)     61(25.6%)         \<0.001\*   7.98±17.17    \<0.001\*   171(71.8%)    67(28.2%)     \<0.001\*
  Death                   618             3.92±1.35                               306(49.5%)     312(50.5%)                    16.85±27.00               286(46.3%)    332(53.7%)    

Note: a Using t test, \* p \< 0.05 was considered statistically significant. b Using Chi-squared test, \* p \< 0.05 was considered statistically significant.

###### 

Fibrinogen and CRP in patients with non-small cell lung cancer by Kaplan-Meier survival analysis (log-rank test).

  Variable        Case   OS (months)            
  --------------- ------ ------------- -------- -----------
  Total           856                           
  Fibrinogen                                    \<0.001\*
  Low level^a^    483    44.752        37.233   
  High level^a^   373    26.623        16.3     
  CRP                                           
  Low level^a^    457    45.235        38.7     \<0.001\*
  High levela     399    27.178        16.433   
  Combination                                   
  both low        401    46.874        40.867   \<0.001\*
  either high     138    32.807        21.133   
  both high       317    25.537        15.067   

\* p \< 0.05, statistically significant.

###### 

Univariate and multivariate COX regression analyses for Overall Survival in patients with non-small cell lung cancer.

  Variables                     Univariate analysis                 Multivariate analysis                                          
  ----------------------------- --------------------- ------------- ----------------------- -- --------------------- ------------- ---------------
  Age (years), (≤61 vs \>61)    0.969 (0.772-1.215)   0.772-1.215   0.783                                                          
  Gender (female vs male)       0.768 (0.641-0.919)   0.641-0.919   **0.004\***                0.877 (0.728-1.057)   0.728-1.057   0.169
  Smoking history (no vs yes)   1.129 (0.961-1.327)   0.961-1.327   0.140                                                          
  Differentiation                                                                                                                  
  G1                            reference             reference     reference                  reference             reference     reference
  G2/G3                         1.663 (1.096-2.523)   1.096-2.523   **0.017\***                1.265 (0.831-1.927)   0.831-1.927   0.273
  Tumor status (T)                                                                                                                 
  T1/T2                         reference             reference     reference                  reference             reference     reference
  T3/T4                         2.34 (1.972-2.777)    1.972-2.777   **\<0.001\***              1.281 (1.063-1.542)   1.063-1.542   **0.009\***
  Nodal status (N\>0/N0)        3.154 (2.651-3.751)   2.651-3.751   **\<0.001\***              1.721 (1.369-2.162)   1.369-2.162   **\<0.001\***
  Distant metastases (M0/M1)    2.606 (2.145-3.165)   2.145-3.165   **\<0.001\***              1.495 (1.214-1.841)   1.214-1.841   **\<0.001\***
  Clinical stage                                                                                                                   
  I/II                          reference             reference     reference                  reference             reference     reference
  III/IV                        3.817 (3.213-4.535)   3.213-4.535   **\<0.001\***              2.009 (1.562-2.583)   1.562-2.583   **\<0.001\***
  Fibrinogen (High/Low)         2.064 (1.761-2.420)   1.761-2.420   **\<0.001\***              1.399 (1.122-1.744)   1.122-1.744   **0.003\***
  CRP (High/Low)                2.047 (1.746-2.401)   1.746-2.401   **\<0.001\***              1.304 (1.040-1.636)   1.040-1.636   **0.022\***

\* p \< 0.05, statistically significant. CI = confidence interval; HR = hazard ratio.

###### 

Point Assignment and Prognostic Score of the nomogram based CRP and fibrinogen.

  Variable and Prognostic Score   Score   Estimated 5-Year Overall Survival (%)
  ------------------------------- ------- ---------------------------------------
  T group Points                          
  T3-T4                           0       
  T1-T2                           61      
  Differentiation Points                  
  G2/G3                           0       
  G1                              49      
  LNM Points                              
  Positive                        0       
  Negative                        89      
  Stage group Points                      
  III-IV                          0       
  I-II                            100     
  Metastasis Points                       
  Positive                        0       
  Negative                        66      
  Fibrinogen group Points                 
  High                            0       
  Low                             56      
  CRP group Points                        
  High                            0       
  Low                             64      
  Total prognostic Score                  
  0-158                                   10
  158-258                                 20
  258-352                                 38
  ≥352                                    40
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